ENVB

Enveric Biosciences, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Other
Website enveric.com
Employees(FY) 25
ISIN US29405E2081

Performance

-8.53%

-8.45%

-33.81%

-51.56%

-75.0%

YTD

-75.93%

Profile

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead program is EB-373, an active metabolite of psilocybin, which is in Phase 1 clinical trials for the treatment of anxiety disorders; EVM-301 for treating mental health; and EV104 CBD + Celecoxib conjugate for treating osteoarthritis. The company also developing cannabinoid-infused topical product for the treatment of radiodermatitis; and cannabinoid and COX-2 inhibitor conjugation that is in pre-clinical stage for the treatment of OA/acute pain. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

Advanced Technical Analysis

Technical Analysis of ENVB 2024-12-20

The stock indicators reflect a bearish sentiment overall, with a Moving Average Score of 3 indicating strong downward pressure, while the Oscillators Score of 50 suggests a neutral stance. The Technical Score of 26 further reinforces the bearish outlook, signaling potential challenges ahead for the stock.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of ENVB

Stock Rank

Recent News & Updates

2024-12-01 19:00
Enveric Biosciences Announces New U.S. Patents Supporting EVM301 Series and EVM201 Series Compounds(Businesswire)
2024-11-24 20:00
Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like Behavior(Businesswire)
2024-11-17 18:19
Weekly Roundup on the Cannabis Sector & Psychedelic Sector(Yahoo Finance)
2024-11-14 03:05
Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results(Businesswire)
2024-11-11 20:00
Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002(Businesswire)
2024-11-03 20:00
Enveric Biosciences Announces Broad Range of Patent Issuances(Businesswire)
2024-10-14 20:00
Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003(Businesswire)
2024-09-25 20:30
Enveric Biosciences Presents Data Highlighting Development of EB-003 at European Behavioral Pharmacology Society Biennial Workshop(Businesswire)
2024-09-24 20:30
Enveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug Summit(Businesswire)
2024-09-03 20:00
Enveric Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference(Businesswire)
2024-08-12 20:00
Aries Science & Technology and Enveric Biosciences Announce Issuance of Key US Patent Under Aries License for Treatment of Radiation Dermatitis and Other Conditions(Businesswire)
2024-08-12 05:30
Enveric Biosciences Reports Second Quarter 2024 Financial and Corporate Results(Businesswire)
2024-07-24 20:00
Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to be Dosed Orally(Businesswire)
2024-07-14 21:02
Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement(Businesswire)
2024-07-09 20:00
Enveric Biosciences Announces Patent Granted for Drug Candidate(Businesswire)
2024-06-27 20:00
Diamond Equity Research Releases Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB)(Globenewswire)
2024-06-24 20:00
Enveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development Candidate(Businesswire)
2024-05-29 20:00
Enveric Biosciences to Participate in BIO International Convention 2024(Businesswire)
2024-05-19 23:54
ENVB Stock Earnings: Enveric Biosciences Beats EPS for Q1 2024(Investorplace)
2024-05-19 19:45
Weekly Roundup on the Cannabis Sector & Psychedelic Sector(Yahoo Finance)
2024-05-14 18:00
Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results(Businesswire)
2024-05-13 20:00
Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders(Businesswire)
2024-05-07 19:00
Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids(Businesswire)
2024-05-02 05:50
Enveric Biosciences, Inc. (ENVB) Stock Falls Amid Market Uptick: What Investors Need to Know(Zacks)
2024-04-12 00:00
What Makes Enveric Biosciences (ENVB) a New Strong Buy Stock(Zacks)
2024-03-31 22:53
ENVB Stock Earnings: Enveric Biosciences Beats EPS for Q4 2023(Investorplace)
2024-03-25 19:00
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023(Businesswire)
2024-03-18 19:00
Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease(Businesswire)
2024-03-11 19:00
Enveric Biosciences Announces New Patent Issuances Protecting Multiple Assets Covered by Non-Binding Term Sheets(Businesswire)
2024-02-29 01:04
Why Is Enveric Biosciences (ENVB) Stock Up 120% Today?(Investorplace)

Page 1 of 5

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.